Onconova Therapeutics and Pangea Biomed announced a research collaboration between the companies. The collaboration will leverage Pangea Biomed’s proprietary algorithmic platform, ENLIGHT, with the goal of identifying biomarkers of response to Onconova’s proprietary investigational product candidate rigosertib. "Rigosertib’s ability to potently inhibit PLK1 and modulate the tumor immune microenvironment confers broad potential to treat a range of solid cancers," said Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova. "By leveraging Pangea’s AI platform to identify predictive biomarkers of response to rigosertib, we aim to inform a precision medicine approach to selecting additional PLK1-dependent tumors and other indications for its potential evaluation. We believe this approach will increase the probability of success for rigosertib’s future development programs."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ONTX:
- Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
- Onconova reports FY22 EPS (91c), consensus (93c)
- Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
- Onconova announces upcoming poster presentations at the AACR annual meeting
- Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting